Onco-innovations Ltd. · NEO:ONCO
Onco-innovations — Investor Presentation (March 2025)
22 slides from Onco-innovations's investor presentation, March 2025
Slide 1: Transforming Oncology Through Science and AI Technology
Transforming Oncology Through Science and AI Technology (CSE - ONCO) (OTCQB: ONNVF) (Frankfurt - W1H) March 2025 Corporate Presentation
Slide 2: Forward Looking Statements and Disclaimer
Forward Looking Statements and Disclaimer Forward Looking Statements This presentation contains "forward looking information" within the meaning of applicable Canadian securities legislation. Wherever possible, words such as "plans", "expects", or "does not expect", "budget", "scheduled", "estimates
Slide 3: With You Today
With You Today Thomas O'Shaughnessy, Richard Heinzl, MD, Steven Jones, PhD, Paul Arora, PhD, CEO of CEO Director Scientific Advisor INKA Health AI Healthcare Strategy Expert | 25 Years Experience Founder, Doctors Without Borders Canada – Nobel Director, Genome Sciences Centre & BC Cancer Epidemiolog
Slide 4: Executive Summary
Executive Summary Onco-Innovations seeks to transform Oncology Through Science, AI, and Strategic Acquisitions Mission-Driven Innovation Novel Drug Pipeline Strategic Acquisition of Market Opportunity and Inka Health Scalability Committed to revolutionizing Proprietary colorectal cancer Integration
Slide 5: Global Cancer Market Size
An Immense Investment Opportunity in Oncology Global Cancer Market Size 10 Year Growth Projection 135% Aggregate Growth Expected by 2032 to $521B • Global cancer cases are projected to rise by 47% by 2040. • CAGR of 8.9% • Existing treatment gaps in precision medicine and early diagnostics. • Addres
Slide 6: Colorectal Cancer: A Critical Focus
Addressing the Second Leading Cause of Cancer Deaths Colorectal Cancer: A Critical Focus 1. Global Impact • Affects 1.9M people annually; causes 700,000 deaths worldwide. • 4th most common cancer; sporadic cases (no family history) account for 70%. 2. Targeted Treatment Matters • 90% survival rate f
Slide 7: Our PNKP Technology
OUR PNKP Technology 100% Owned PNKP Technology Focused on Oncology Innovation Our platform technology focuses on Polynucleotide Kinase 3'-Phosphatase (PNKP) inhibitors. • Key Innovation: Targets Polynucleotide Kinase 3'-Phosphatase (PNKP) with aim to block DNA repair in cancer cells. Polynucleotide
Slide 8: ONC010: The Next-Generation Drug Formulation
ONC010 : The Next-Generation Drug Formulation Our Proprietary Lead Drug Candidate Utilizing PNKP Technology (A83B4C63) • Cancer-Targeted Approach Proprietary Formula: Aims to prevent DNA repair to eliminate cancer cells. Enhanced Delivery: Nanoparticles assist precision targeting. Optimized Results:
Slide 9: Preclinical Validation - Colorectal Drug Success
Preclinical Validation - Colorectal Drug Success Preclinical Validation: Tumor Reduction and Survival Impact Existing Results in Animal Models • Studies reveal NP/A83B4C63, a novel nanoparticle formulation, demonstrating efficacy in slowing down the growth of PTEN-/- tumors. • Compared to placebo, N
Slide 10: Path to Regulatory Approval
Path to Regulatory Approval A Regulatory Roadmap for PNKP Drug Candidates Validated Preclinical Data: Regulatory Milestones: Fast-Track Eligibility: Global Multi-Region Strategy: Plans include submissions to the FDA, EMA, and Asia-Pacific regulatory agencies to maximize international market reach. 1
Slide 11: Executive Team and Board of Directors
Thomas Richard Heinzel Nico Mah O'Shaughnessy Director CFO CEO Founder, Doctors Without Borders Chartered Professional Accountant Healthcare Strategy Expert | 25 Years Canada – Nobel Peace Prize (1999) (CPA) with nearly 8 years of experience. Experience Former Partner, Deloitte CEO, My Next Health I
Slide 12: Scientific and Clinical Advisory Board
Dr. Michael Weinfeld Dr. Frederick West Dr. Afsaneh Lavasanifar Dr. Weinfeld, Professor of Oncology at the Dr. West, Allard Research Chair in Oncology at the Dr. Lavasanifar, Professor in Pharmaceutics at the University of Alberta and Senior Scientist at Alberta University of Alberta, specializes in
Slide 13: Inka Health: Transforming Oncology Through SynoGraph AI
Inka Health: Transforming Oncology Through SynoGraph AI Transformative Acquisition to Lead the Future of Oncology • Acquisition Details • 100% Acquisition of Inka Health AI for $3M in Onco common shares. • Closed: February 4, 2025. • SynoGraph AI Integration • Novel AI: Accelerates identification of
Slide 14: Inka Scientific Leadership Team
Inka Scientific Leadership Team World-Class Oncology-AI Focused Team Paul Arora, CEO, PhD Steven Jones, PhD Winson Cheung, MD James Orbinski, MD Epidemiologist Director, Genome Sciences Centre and BC Cancer Medical Oncologist (GI) Scientific Advisor Successfully exited founder of Lighthouse Outcomes
Slide 15: Inka's Proprietary and Patented AI SynoGraph
Inka's Proprietary and Patented AI SynoGraph SynoGraph is Inka's flagship asset, a revolutionary AI-enabled platform that aims to enhance the precision and efficiency of oncology diagnostics and treatment planning. Real-time visualization of tumor networks for targeted therapy design Supports adapti
Slide 16: SynoGraph
& &} Oy ae r SYNOGRAPH™ Pathology Genetic Gene imine) Biological Pharmaco- Public Published Regulatory’ KOL Turn Complexity into Clarity EHR/claims __reports Imaging sequencing expression chemistry relationships | dynamics datasets Papers | HTAappraisals. opinion SynoGraph Network-based causal Al 1.
Slide 17: Our Big Pharma Clients
Our Big Pharma Clients And... Our Data Partners Make us a unique value proposition. Big Pharma Clients and World-Class, Exclusive Data Partners
Slide 18: ONCO + INKA
ONCO + INKA Uniting Cutting-Edge AI with Novel Therapies to accelerate cancer diagnosis and treatment • Onco Innovations Completely new class of therapy: Novel mechanism of action (patented PNKP inhibitors) and Onco10 drug formulation augments existing therapies (chemo and radiation). Targeted Deliv
Slide 19: ONCO Public Company Comps
ONCO Public Company Comps A Unique AI-Driven Biotech Advancing the Future of Cancer Therapeutics Biotech or Clinical Market Cap Company Product Pipeline AI Trial (in USD) Exchange Kura Oncology, Inc. (KURA) KO-2806 FTI inhibitor – focus on kidney cancer Biotech Phase 1 $632 NASDAQ-GS Verastem Oncolo
Slide 20: Onco-Innovations Milestones
Onco-Innovations Milestones Achieved and Anticipated List in Europe and USA Anticipated secondary Begin Phase 1 Trial listings on Euronext and November 2024 Advance Pre- OTCQX expanding investor For drug candidate of clinical studies base colorectal cancer with PNKP Successful IPO on CSE @ technolog
Slide 21: Highlights of Onco-Innovations
Highlights of Onco-Innovations Why Onco-Innovations? An Undervalued Unique Opportunity in Oncology • Proprietary Drug Portfolio • Revolutionary colorectal cancer therapies addressing an initial and growing $15 billion market. • Fully owned PKNP technology and ONC010 for targeted drug development and
Slide 22: Onco-Innovations HQ
Onco-Innovations HQ Tel: 1 (888) 261 –8055 https://oncoinnovations.com investors@oncoinnovations.com 1309 – 7th Street SW Calgary, Alberta, Canada T2R 1A5
Onco-Innovations — Investor Presentation (March 2025) on 6ix